The Illegal Retatrutide Market: Sky News reveals the latest MHRA crackdown
A convincing video, a friendly direct message or a recommendation from someone at the gym can make a product feel safe and trustworthy.
Sky News’ latest reporting on retatrutide reveals the scale of illegal versions of the experimental medicine being offered through social media, while the UK regulator has seized even more products purporting to be retatrutide.
For anyone tempted by a social-media recommendation, the message is clear: a convincing advertisement, a familiar-looking pen or a seller’s reassurance cannot establish what is inside the product.
Here, we look at Sky’s findings and the MHRA operations behind the growing underground market of manufacturing and supplying products claiming to be retatrutide.
What did Sky News report?
Sky News went undercover to discover an unlicensed weight-loss drug being sold illegally online in the UK, with underground laboratories believed to be producing their own versions. Its accompanying coverage says reporters found sellers offering bulk orders of retatrutide from China.
The reporting also describes a woman from Yorkshire, Faye Firth, who ended up in hospital after a severe allergic reaction to a product bought on Facebook
"I thought this was my time" said Faith, describing the moment she feared she could die. Faith, a beautician, bought a product online claiming to be Retatrutide. She suffered a severe allergic reaction and struggled to breath.
When asked if they were surprised by what had happened to Faye, Chief Safety Office of the MHRA, Alison Cave, said that she was not. Alison backed up warnings of buying medications on social media.
"You do not know what you are buying. You do not know what is in the product. They are manufactured by organised criminal gangs".
Why retatrutide’s research status matters
Retatrutide is being studied as a medicine acting on three hormone receptors: GIP, GLP-1 and glucagon. Lilly has reported results from several Phase 3 studies, with additional trials continuing. Promising results do not amount to regulatory authorisation.
As at 8 November 2026, retatrutide is not authorised in the UK. Products offered to the public as retatrutide are not an approved alternative to prescribed treatment. Yet products claiming to be Retatrutide are being sold online, prompting the regulators to act, including arrests and raids.
The MHRA seizures: a timeline
The Medicines and Healthcare products Regulatory Agency (MHRA) has described repeated operations involving suspected illegal weight-loss medicine production and supply. These reports cover products labelled as retatrutide and tirzepatide, alongside other materials; the figures should not all be described as retatrutide.
October 2025: a retatrutide production facility in Northampton
In its 24 October 2025 release, the MHRA reported finding more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch, tens of thousands of empty pens and raw chemical ingredients. It described the site as the first illicit weight-loss medicine production facility discovered in the UK.
This went beyond a few suspicious parcels: the regulator had found materials for producing and assembling further products.
February 2026: another suspected manufacturing operation
On 25 February 2026, the MHRA announced action involving a farm near Sleaford and a residential address in Grantham. Almost 2,000 doses of unauthorised weight-loss medicines were awaiting dispatch. Officers also seized manufacturing equipment, suspected pharmaceutical ingredients, packaging and commercial vehicles.
The agency said the investigation concerned suspected manufacture and distribution of unlicensed medicines, including products sold as retatrutide and tirzepatide. Suspicions and investigations should not be confused with convictions.
May 2026: around 12,000 doses seized
The MHRA’s 29 May release described a raid the previous day at a country estate near Northampton. Around 12,000 doses of unlicensed weight-loss medicines were seized, along with packaging materials and suspected pharmaceutical substances. Two people were arrested on suspicion of offences under medicines legislation.
At the time, the agency described this as its largest-ever seizure of unlicensed weight-loss medicines. An arrest is not a finding of guilt.
October 2026: over 12,000 fake pens in Birmingham
On 14 October, the MHRA and West Midlands Police raided an industrial unit in Birmingham. The following day’s announcement reported over 12,000 fake retatrutide and tirzepatide pens, plus packaging for around 30,000 more products. The estimated value was £2 million.
The regulator warned that these products had not been assessed for safety, quality or effectiveness. The seizure illustrates why professional-looking packaging cannot provide reassurance about an unregulated supply chain.
A note on the numbers: the October 2025 announcement reported more than 2,000 finished pens; the MHRA’s October 2026 retrospective gives 5,000 for that earlier operation. This timeline uses the original announcement. Pens, doses, empty devices and packaging are different measures and must not be added together as a single total.
What does this mean for you?
The combined picture is of repeated suspected production and supply activity, rather than a risk confined to one seller or one area. This is everywhere in the UK thanks to the ease of access to social media. It does not prove that every seized product came from the same network, or that every product offered online has the same contents.
Whether an offer arrives through Facebook, a gym contact or a private message, the major red flag is if there is no proper clinical assessment of your health. Testimonials and claims of ‘pharmaceutical grade’ are not substitutes for those checks.
Already bought or used "Retatrutide"?
Do not take another dose of an unknown product. Seek prompt medical advice and keep the packaging and seller details to help clinicians and investigators. If you are worried you may have been harmed and are unsure what to do, contact NHS 111. Call 999 for severe symptoms such as difficulty breathing or collapse.
Your safety comes first
Ensure you're choosing a safe and legitimate provider. Behind all the hype, your safety is paramount. Look for a provider that offers a professional, confidential and patient-led service, giving you space to discuss your health, concerns and goals without judgement.
The purpose of seeking professional support is a proper assessment, clear information and appropriate follow-up.
Retatrutide should not be bought from unofficial sellers while it remains unauthorised for human use (beyond clinical trials). If you do have any concerns, you can reply to this email or contact the MHRA directly.
Sources and further reading
Information checked on 8 November 2026. This article provides general information and does not replace individual medical advice. Images are illustrative and do not depict the people or premises in the reports.
